Cover Image
市場調查報告書

Asklepios BioPharmaceutical, Inc.:產品平台分析

Asklepios BioPharmaceutical, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 257900
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Asklepios BioPharmaceutical, Inc.:產品平台分析 Asklepios BioPharmaceutical, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月20日 內容資訊: 英文 23 Pages
簡介

Asklepios BioPharmaceutical, Inc.是總公司設立於美國的生物科技企業。開發·提供新蛋白質及細胞性醫藥品。利用BNP這個遺傳基因遞送技術平台來開發肌肉萎縮症,B型血友病,鬱血性心衰竭,癲癇,A型血友病,色素性視網膜炎,骨關節炎等治療藥。

本報告提供Asklepios BioPharmaceutical, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

Asklepios BioPharmaceutical, Inc. 的基本資料

  • Asklepios BioPharmaceutical, Inc. 概要
  • 主要資訊
  • 企業資料

Asklepios BioPharmaceutical, Inc. :R&D概要

  • 主要的治療範圍

Asklepios BioPharmaceutical, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Asklepios BioPharmaceutical, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Asklepios BioPharmaceutical, Inc. :藥物簡介

  • Biostrophin
  • BNP-CHF
  • BNP-TLE
  • BNP-OA
  • BNP-RP

Asklepios BioPharmaceutical, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Asklepios BioPharmaceutical, Inc. :最新的開發平台資訊

Asklepios BioPharmaceutical, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07065CDB

Summary

Global Markets Direct's, 'Asklepios BioPharmaceutical, Inc. - Product Pipeline Review - 2015', provides an overview of the Asklepios BioPharmaceutical, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Asklepios BioPharmaceutical, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Asklepios BioPharmaceutical, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Asklepios BioPharmaceutical, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Asklepios BioPharmaceutical, Inc.'s pipeline products

Reasons to buy

  • Evaluate Asklepios BioPharmaceutical, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Asklepios BioPharmaceutical, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Asklepios BioPharmaceutical, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Asklepios BioPharmaceutical, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Asklepios BioPharmaceutical, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Asklepios BioPharmaceutical, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Asklepios BioPharmaceutical, Inc. Snapshot
    • Asklepios BioPharmaceutical, Inc. Overview
    • Key Information
    • Key Facts
  • Asklepios BioPharmaceutical, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Asklepios BioPharmaceutical, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Asklepios BioPharmaceutical, Inc. - Pipeline Products Glance
    • Asklepios BioPharmaceutical, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Asklepios BioPharmaceutical, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Asklepios BioPharmaceutical, Inc. - Drug Profiles
    • Biostrophin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BNP-CHF
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BNP-TLE
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BNP-OA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BNP-RP
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Asklepios BioPharmaceutical, Inc. - Pipeline Analysis
  • Asklepios BioPharmaceutical, Inc. - Pipeline Products by Target
  • Asklepios BioPharmaceutical, Inc. - Pipeline Products by Route of Administration
  • Asklepios BioPharmaceutical, Inc. - Pipeline Products by Molecule Type
  • Asklepios BioPharmaceutical, Inc. - Pipeline Products by Mechanism of Action
  • Asklepios BioPharmaceutical, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Asklepios BioPharmaceutical, Inc., Key Information
  • Asklepios BioPharmaceutical, Inc., Key Facts
  • Asklepios BioPharmaceutical, Inc. - Pipeline by Indication, 2015
  • Asklepios BioPharmaceutical, Inc. - Pipeline by Stage of Development, 2015
  • Asklepios BioPharmaceutical, Inc. - Monotherapy Products in Pipeline, 2015
  • Asklepios BioPharmaceutical, Inc. - Phase I, 2015
  • Asklepios BioPharmaceutical, Inc. - Preclinical, 2015
  • Asklepios BioPharmaceutical, Inc. - Discovery, 2015
  • Asklepios BioPharmaceutical, Inc. - Pipeline by Target, 2015
  • Asklepios BioPharmaceutical, Inc. - Pipeline by Route of Administration, 2015
  • Asklepios BioPharmaceutical, Inc. - Pipeline by Molecule Type, 2015
  • Asklepios BioPharmaceutical, Inc. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Asklepios BioPharmaceutical, Inc. - Pipeline by Top 10 Indication, 2015
  • Asklepios BioPharmaceutical, Inc. - Pipeline by Stage of Development, 2015
  • Asklepios BioPharmaceutical, Inc. - Monotherapy Products in Pipeline, 2015
  • Asklepios BioPharmaceutical, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top